2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysis
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates
1999
Linking Health-Related Quality-of-Life Indicators to Large National Data Sets
Rizzo J, Sindelar J. Linking Health-Related Quality-of-Life Indicators to Large National Data Sets. PharmacoEconomics 1999, 16: 473-482. PMID: 10662394, DOI: 10.2165/00019053-199916050-00005.Peer-Reviewed Original ResearchConceptsNational Medical Expenditure SurveyHealth Utilities IndexEuroQol measureMedical Expenditure SurveyLife indicatorsExpenditure SurveyConsequences of healthAlternate specificationsLarge national data setsEmpirical situationsNational data setsRepresentative data setsUtility indexSensitivity analysisData setsIndicatorsHealth indicatorsEuroQolSpecificationMeasuresPrevious matches